A Randomised trial assessing Efficacy and safety of Mineralocorticoid receptor Antagonist therapy compared to Standard antihypertensive Therapy in hypErtension with low Renin (REMASTER)

Phase 4

Recruiting

• Conditions: ow-renin hypertension; Low-renin hypertension; Metabolic and Endocrine - Other endocrine disorders; Cardiovascular - Hypertension

• Registration Number: ACTRN12622000391774
• Lead Sponsor: Dr Jun Yang

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-03-07
• Last Update Posted: 22 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Adults with hypertension, defined as a mean seated blood pressure > 140/90 mmHg, who are treatment naïve or are receiving up to two antihypertensive agents, and
2. Have a low plasma renin concentration defined as < 10 mU/L, and
3. Can provide informed consent.

Exclusion Criteria

1. Blood pressure >180/120 mmHg
2. On medications confounding plasma renin concentration or plasma aldosterone concentration such as glucocorticoids, oestrogen-containing oral contraceptive pill and hormone replacement therapy and sodium-glucose co-transporter 2 inhibitors
3. Pregnant, breastfeeding or women of child-bearing potential
4. Uncontrolled diabetes with a glycosylated haemoglobin (HbA1C) > 7.5%
5. Chronic kidney disease with an estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73m2
6. Heart failure class II-IV, ischaemic heart disease, transient ischaemic attack, stroke or atrial fibrillation
7. Liquorice abuse
8. Known secondary cause of hypertension (primary hyperparathyroidism, PA defined as PAC post-SST>162 pmol/L where PAC was measured by liquid chromatography-tandem mass spectrometry or > 170 pmol/L where PAC was only measured by radioimmunoassay, autonomous cortisol secretion, hyperthyroidism, phaeochromocytoma, renal artery stenosis or known monogenic causes of low-renin hypertension
9. Hypersensitivity to the trial medications.
10. Potassium > 5.0mmol/

Study & Design

• Study Type: Interventional
• Study Design: Not specified